My research is focused on resistance mechanisms to olaparib in ovarian cancer cells and novel target therapies increasing antitumor activity to PARP inhibitors by inhibiting the ATR/CHK1 pathway. Studies are conducted in vitro and in vivo to provide comprehensive insights into mechanisms associated with overcoming acquired resistance to olaparib.
University of Lodz
Łódź, Łódzkie, Poland
Department of Medical Biophysics